SwePub
Sök i LIBRIS databas

  Extended search

id:"swepub:oai:DiVA.org:bth-26212"
 

Search: id:"swepub:oai:DiVA.org:bth-26212" > Lot-to-lot immunoge...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Ferguson, MurdoColchester Research Group, Canada (author)

Lot-to-lot immunogenicity consistency of the respiratory syncytial virus prefusion F protein vaccine in older adults

  • Article/chapterEnglish2024

Publisher, publication year, extent ...

  • Elsevier,2024
  • electronicrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:bth-26212
  • https://urn.kb.se/resolve?urn=urn:nbn:se:bth-26212URI
  • https://doi.org/10.1016/j.jvacx.2024.100494DOI
  • https://lup.lub.lu.se/record/29ffab4a-56ce-48de-bb98-8912cd79fa75URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Background: Previous phase 3 studies showed that the AS01E-adjuvanted respiratory syncytial virus (RSV) prefusion F protein-based vaccine for older adults (RSVPreF3 OA) is well tolerated and efficacious in preventing RSV-associated lower respiratory tract disease in adults ≥ 60 years of age. This study evaluated lot-to-lot immunogenicity consistency, reactogenicity, and safety of three RSVPreF3 OA lots. Methods: This phase 3, multicenter, double-blind study randomized (1:1:1) participants ≥ 60 years of age to receive one of three RSVPreF3 OA lots. Serum RSVPreF3-binding immunoglobulin G (IgG) concentration was assessed at baseline and 30 days post-vaccination. Lot-to-lot consistency was demonstrated if the two-sided 95 % confidence intervals (CIs) of the RSVPreF3-binding IgG geometric mean concentration (GMC) ratios between each lot pair at 30 days post-vaccination were within 0.67 and 1.50. Solicited adverse events (AEs) within four days, unsolicited AEs within 30 days, and serious AEs (SAEs) and potential immune-mediated diseases within six months post-vaccination were recorded. Results: A total of 757 participants received RSVPreF3 OA, of whom 708 were included in the per-protocol set (234, 237, and 237 participants for each lot). Lot-to-lot consistency was demonstrated: GMC ratios were 1.06 (95 % CI: 0.94–1.21), 0.92 (0.81–1.04), and 0.87 (0.77–0.99) between the lot pairs (lot 1/2; 1/3; 2/3). For the three lots, the RSVPreF3-binding IgG concentration increased 11.84-, 11.29-, and 12.46-fold post-vaccination compared to baseline. The reporting rates of solicited and unsolicited AEs, SAEs, and potential immune-mediated diseases were balanced between lots. Twenty-one participants reported SAEs; one of these–a case of atrial fibrillation–was considered by the investigator as vaccine-related. SAEs with a fatal outcome were reported for four participants, none of which were considered by the investigator as vaccine-related. Conclusion: This study demonstrated lot-to-lot immunogenicity consistency of three RSVPreF3 OA vaccine lots and indicated that the vaccine had an acceptable safety profile. ClinicalTrials.gov: NCT05059301. © 2024 GSK

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Murray, AlexanderPharmQuest, USA (author)
  • Pliamm, LewCanadian Phase Onward Inc, Canada (author)
  • Rombo, LarsUppsala University,Clinical Research Centre Sörmland (author)
  • Sanmartin Berglund, Johan,ProfessorBlekinge Institute of Technology,Lund University,Lunds universitet,Blekinge Tekniska Högskola,Institutionen för hälsa,Geriatrik,Forskargrupper vid Lunds universitet,Geriatric Medicine,Lund University Research Groups,Geriatrics(Swepub:lu)smi-jbe (author)
  • David, Marie-PierreGSK, Belgium,GlaxoSmithKline Pharmaceuticals SA (author)
  • De Schrevel, NathalieGSK, Belgium,GlaxoSmithKline Pharmaceuticals SA (author)
  • Maschino, FranckGSK, Belgium,GlaxoSmithKline Pharmaceuticals SA (author)
  • Kotb, ShadyGSK, Belgium,GlaxoSmithKline Pharmaceuticals SA (author)
  • Olivier, AurélieGSK, Belgium,GlaxoSmithKline Pharmaceuticals SA (author)
  • Hulstrøm, VeronicaGSK, Belgium,GlaxoSmithKline Pharmaceuticals SA (author)
  • Colchester Research Group, CanadaPharmQuest, USA (creator_code:org_t)

Related titles

  • In:Vaccine: X: Elsevier182590-1362

Internet link

Find in a library

  • Vaccine: X (Search for host publication in LIBRIS)

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view